Publications by authors named "Steven Sun"

Claim this Profile
F
Forward genetics identifies HN1L/JPT2 as a novel carboplatin resistance gene in ovarian cancer.
Han Wei, Aishat Motolani, Kenneth P Nephew, Guanglong Jiang, Faranak Alipourgivi, Steven Sun

Genes Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure.
Steven Sun, Mina Nikanjam, Mark Mirochnick, Kathleen M Powis, Ahizechukwu C Eke

J Clin Pharmacol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.
Himanshu Savardekar, Andrew Stiff, Alvin Liu, Robert Wesolowski, Emily Schwarz, Steven H Sun, Debasish Sundi

J Clin Invest· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy.
Steven Sun, Kenneth Cardona, William W Tseng

Cancer Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
Colin D Angell, Steven H Sun, Gabriella Lapurga, Brooke Benner, Dionisia Quiroga

Melanoma Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All?
William W Tseng, Francesco Barretta, Francesco Tucci, Marta Barisella, Stefano Radaelli, Steven H Sun

J Surg Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
Emily Schwarz, Brooke Benner, Robert Wesolowski, Dionisia Quiroga, Logan Good, Steven H Sun

JCI Insight· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate.
Colin D Angell, Gabriella Lapurga, Steven H Sun, Courtney Johnson, Himanshu Savardekar

Nanomaterials (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of rectal cancer patients who refuse surgery after incomplete clinical response to neoadjuvant therapy.
Kevin P Labadie, Kristofor A Olson, Steven H Sun, Philip H G Ituarte, Mark Hanna

J Surg Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework.
Hans-Jochen Weber, Stephen Corson, Jiang Li, François Mercier, Satrajit Roychoudhury, Steven Sun

Pharm Stat· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
Steven H Sun, Colin D Angell, Himanshu Savardekar, Debasish Sundi, David Abood

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
Peter W M Johnson, Sriram Balasubramanian, Brendan Hodkinson, S Martin Shreeve, Steven Sun

Blood Adv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib.
Erick J Carlson, Himanshu Savardekar, Xiaojun Hu, Gabriella Lapurga, Courtney Johnson, Steven H Sun

ACS Pharmacol Transl Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression Patterns of microRNAs and Associated Target Genes in Ulcerated Primary Cutaneous Melanoma.
Mallory J DiVincenzo, Emily Schwarz, Casey Ren, Zoe Barricklow, Maribelle Moufawad, Steven Sun

J Invest Dermatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Pharmacokinetics and Injection Site Histopathology in Nude Mice Treated with Long-acting Buprenorphine Formulations.
Jacqueline A Illario, Kent G Osborn, Arnold V Garcia, Yadira J Sepulveda, Jeremiah D Momper, Steven A Sun

J Am Assoc Lab Anim Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
G A Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz, Steven Sun

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor.
Long Zhang, Nicolas Burns, Zhouxiang Ji, Steven Sun, Susan L Deutscher

Nanomedicine· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue.
Lakshmi Prabhu, Matthew Martin, Lan Chen, Özlem Demir, Jiamin Jin, Mengyao Sun, Steven Sun

Genes Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial.
Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Steven Sun

EJHaem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Ciara L Freeman, Prasath Pararajalingam, Ling Jin, Sriram Balasubramanian, Aixiang Jiang, Steven Sun

Leukemia· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Steven Sun, Yazdi K Pithavala, Jean-François Martini, Joseph Chen

J Clin Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using VBIM Technique to Discover ARMC4/ODAD2 as a Novel Negative Regulator of NF-κB and a New Tumor Suppressor in Colorectal Cancer.
Matthew Martin, Rasika Mundade, Antja-Voy Hartley, Guanglong Jiang, Jiamin Jin, Steven Sun

Int J Mol Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, Katja Weisel, Meletios A Dimopoulos, Steven Sun

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
Steven H Sun, Brooke Benner, Himanshu Savardekar, Gabriella Lapurga, Logan Good

Front Immunol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Sriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, Nathan H Fowler, Judith Trotman, Steven Sun

Cancer Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis